BSEM Q2 results blew it out of the water! This OTC stock is heading to the NASDAQ!

$74 Million In Q2 And What that means for this Biotech stock  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ [stocksearning]( [Unsubscribe]( A message from Sideways Frequency [Second quarter financial results are in for BSEM, prompting another price target increase from Zack’s!]( Why might Zack’s Small Cap Research bullish on BioStem Technologies, Inc. (OTC:BSEM) with a $24.25 price target now? One reason is another quarter of explosive revenues! The company released its 2Q2024 earnings results, which vastly exceeded estimates as revenue growth accelerated, and the company posted profits that exceeded even Zack’s projections. Details include: Revenues of $74.5 million represented a nearly 74-fold increase over the year-ago period. Margins remained at 95%, and management believes the company will be able to maintain that level. In the call following the announcement, the company also spoke about the [uplisting of BSEM stock to the NASDAQ stock exchange and believes that process should be complete in the next 60-90 days!]( Zack’s has reiterated its belief the BSEM is still underpriced even after its recent move higher and continues to represent a good opportunity at recent prices for investors to get in before what the firm believes will be a more aggressive move higher in the not-too-distant future. [BioStem Technologies, Inc. (OTC:BSEM)]( is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. Regenerative medicine is one of the most exciting arenas in medicine and BSEM is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. [BSEM’s]( proprietary processing method and its placental allograft products have been published in the international, peer-reviewed journal, Health Science Reports. The study’s primary objective was to evaluate and compare the effectiveness of two wound care products for managing diabetic foot ulcers, including BioStem’s AmnioWrap2® (RE-AC), processed using the BioREtain® method, and (L-AC) processed through a more ablative method used by a leading competitor in the industry. The study found that RE-AC products required fewer applications, suggesting greater efficiency in managing wounds, and that they offered overall better efficiency! The company has retained an experienced clinical research professional to lead BioStem’s Diabetic Foot Ulcer and Venous Leg Ulcer trials which is something to keep your eyes on! [With products leading to cost savings, revenues exploding and a future uplisting to the NASDAQ exchange, BSEM is an exciting company to watch in the medtech space!]( --------------------------------------------------------------- This message is a PAID ADVERTISEMENT for BioStem Technologies Inc. (OTC: BSEM) from Sideways Frequency. StockEarnings, Inc. has received a fixed fee of $3500.00 from Sideways Frequency for multiple Dedicated Email Sends, Newsletter Sponsorships, SMS Sends, and Banner Display Ads between September 10, 2024 and September 16, 2024. Other than the compensation received for this advertisement sent to subscribers, StockEarnings and its principals are not affiliated with either BioStem Technologies Inc. (OTC: BSEM) or Sideways Frequency. StockEarnings and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither StockEarnings nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from StockEarnings to buy or sell any security. StockEarnings has not evaluated the accuracy of any claims made in this advertisement. StockEarnings recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding BioStem Technologies Inc. (OTC: BSEM) on Huge Alerts website for additional information about the relationship between Sideways Frequency and BioStem Technologies Inc. (OTC: BSEM). Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click [Unsubscribe](. StockEarnings, Inc 33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA W: 877.6.STOCKS StockEarnings.com